Expansion of Business Domains through Healthcare, Digital and Venture Investments
First written in FY2022. 4 of 6 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Preparations are under way for the launch of Saeful, a cognitive-function supplement newly accepted for notification as a food with function claims. At michiteku Co., Ltd., we offer michiteku Web, a tool supporting emotional care immediately after diagnosis for patients with colorectal, gastric, lung, breast, cervical and endometrial cancer, and improving health literacy so that they can understand what their doctors tell them, as well as michiteku YOHA, an app for managing hospital visit dates that supports balancing daily life with treatment.」
Regarding the expansion of business domains, preparations are under way for the launch of the cognitive-function supplement Saeful, the target cancer types for michiteku Web are being expanded, and michiteku YOHA is being offered. - FY2025AdvancedAnnual report
「In addition, michiteku Co., Ltd. offers the beta version of michiteku, a tool supporting emotional care immediately after diagnosis for patients with colorectal, gastric, lung and breast cancer, and improving health literacy so that they can understand what their doctors tell them. In January 2025, it also began offering michiteku YOHA, an app for managing hospital visit dates that supports balancing daily life with treatment.」
The beta version of michiteku continues to be offered for a broader range of cancer types, and michiteku YOHA, an app for managing hospital visit dates, was launched in January 2025. - FY2024AdvancedAnnual report
「To use digital technologies to address customers’ unresolved needs and pursue the creation of new value, michiteku Co., Ltd. began offering in May 2023 a beta version of michiteku, a tool supporting emotional care immediately after diagnosis for patients with cancer, including colorectal and gastric cancer, and improving health literacy so that they can understand what their doctors tell them.」
Following the establishment of michiteku, a beta version of a health-literacy support tool for cancer patients was launched in May 2023. - FY2024-Q1RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased by ¥1,800 million, or 8.1%, year on year to ¥23,500 million, due to increases in co-promotion fees accompanying higher sales of Forxiga Tablets and expenses related to strengthening the IT- and digital-related information infrastructure.」
Costs related to strengthening digital information infrastructure continue to be incurred, and efforts to develop the business platform, including the use of digital technologies, are ongoing. - FY2023AdvancedAnnual report
「To use digital technologies to address customers’ unresolved needs and pursue the creation of new value, we established michiteku Co., Ltd. in 2022. In addition, we established Ono Digital Health Investment GK and aim to create and expand new businesses through investments in healthcare ventures.」
The expansion of business domains beyond prescription pharmaceuticals has taken concrete form through the establishment of michiteku, the establishment of a digital health investment company and investments in healthcare ventures. - FY2022First statedAnnual report
「We are expanding our business domains to address growing needs in healthcare and continue providing new value. Last year, we established Ono Pharmaceutical Healthcare Co., Ltd., whose main businesses include foods with function claims. This year, we launched REMWELL, a sleep supplement with function claims that makes maximum use of assets we have developed through our research and development of prescription pharmaceuticals. As a pioneer in lipid research, we will continue working to address a range of health issues through our lipid supplement business. We will also use digital technologies to address customers’ unresolved needs and pursue the creation of new value. In parallel with these activities, we aim to create and expand new businesses through investments in healthcare ventures.」
The expansion of business domains beyond prescription pharmaceuticals was explicitly identified as a growth strategy for the first time, citing the establishment of a healthcare subsidiary, the launch of a sleep supplement, the use of digital technologies and investments in healthcare ventures.